Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase

British Journal of Cancer, 05/07/2012

Arginine–depleting therapy with pegylated arginine deiminase (ADI–PEG20) is safe and the drug is only efficacious in melanoma patients whose tumour has negative argininosuccinate synthetase (ASS) expression. Argininosuccinate synthetase tumour positivity is associated with drug resistance and tumour progression.

Print Article Summary